


PHARMACEUTICAL 2018



Akebia Therapeutics Inc. Rank 114 of 349





PHARMACEUTICAL 2018



Akebia Therapeutics Inc. Rank 114 of 349

The relative strengths and weaknesses of Akebia Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Akebia Therapeutics Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 243% points. The greatest weakness of Akebia Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is -60%, being 218% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	358,356
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	144,349
Liabilities, Non-Current	22
Other Assets	2,274
Other Compr. Net Income	-400
Other Expenses	0
Other Liabilities	100,545
Other Net Income	180,987
Property and Equipment	3,617
Research and Development	230,893
Revenues	0
Selling, General and Administrative Expense	27,008

Output Variable	Value in 1000 USD
Assets	364,247
Liabilities	244,916
Expenses	257,901
Stockholders Equity	119,331
Net Income	-76,914
Comprehensive Net Income	-77,114
Economic Capital Ratio	-60%